Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538926 | 0.88 | POLB (0.39) | POLBTP53LMNAADORA2AADORA1 | |
| SCHEMBL6539142 | 0.88 | ADORA2A (0.36) | POLBTP53LMNAADORA2AMAPT | |
| SCHEMBL6539249 | 0.81 | TP53 (0.40) | POLBTP53LMNAMAPTMEN1 | |
| SCHEMBL6133393 | 0.81 | ADORA1 (0.48) | LMNAADORA2AMAPTKMT2AADORA1 | |
| SCHEMBL6538377 | 0.81 | SRC (0.41) | TP53LMNAFGFR1FGFR2FGFR3 | |
| SCHEMBL6538300 | 0.80 | PIK3CG (0.46) | POLBTP53LMNAADORA2AADORA1 | |
| SCHEMBL6538310 | 0.80 | BRD4 (0.42) | TP53ADORA2AMAPTMEN1KMT2A | |
| SCHEMBL6538523 | 0.80 | TP53 (0.42) | POLBTP53LMNAMAPTMEN1 | |
| SCHEMBL6538477 | 0.79 | ADORA2A (0.38) | POLBTP53ADORA2AADORA1 | |
| SCHEMBL6539046 | 0.79 | TP53 (0.45) | TP53LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067955-A1 | Pyridazinone compound and pharmaceutical use thereof | ADORA1, ADORA2A, P2RX5 | POLB 2406/4885TP53 3830/4885LMNA 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.